+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Factor VIII"

From
From
From
From
Hemophilia Market Report 2026 - Product Thumbnail Image

Hemophilia Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Coagulation Factor Deficiency Market Report 2026 - Product Thumbnail Image

Coagulation Factor Deficiency Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
Hemophilia Drugs - Global Strategic Business Report - Product Thumbnail Image

Hemophilia Drugs - Global Strategic Business Report

  • Report
  • July 2026
  • 196 Pages
  • Global
From
From
From
Synthetic Blood Substitutes and Blood Products Market Report 2026 - Product Thumbnail Image

Synthetic Blood Substitutes and Blood Products Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Von Willebrand's Disease - Pipeline Insight, 2026 - Product Thumbnail Image

Von Willebrand's Disease - Pipeline Insight, 2026

  • Clinical Trials
  • May 2026
  • 60 Pages
  • Global
From
Rare Hemophilia Factors - Global Strategic Business Report - Product Thumbnail Image

Rare Hemophilia Factors - Global Strategic Business Report

  • Report
  • July 2026
  • 132 Pages
  • Global
From
Acquired Hemophilia a Epidemiology Forecast 2026-2035 - Product Thumbnail Image

Acquired Hemophilia a Epidemiology Forecast 2026-2035

  • Report
  • May 2026
  • 150 Pages
  • Global
From
Hemophilia a Epidemiology Forecast 2026-2035 - Product Thumbnail Image

Hemophilia a Epidemiology Forecast 2026-2035

  • Report
  • May 2026
  • 100 Pages
  • Global
From
From
Hemophilia Drug Pipeline Analysis Report 2026 - Product Thumbnail Image

Hemophilia Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • May 2026
  • 150 Pages
  • Global
From
From
Hemophilia Market - Forecast from 2026 to 2031 - Product Thumbnail Image

Hemophilia Market - Forecast from 2026 to 2031

  • Report
  • January 2026
  • 149 Pages
  • Global
From
Loading Indicator

The Factor VIII market is a segment of the hematological drugs market, which includes drugs used to treat blood-related disorders. Factor VIII is a protein that helps blood to clot, and is used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. Factor VIII is typically administered intravenously, and is available in both recombinant and plasma-derived forms. The Factor VIII market is highly competitive, with a number of companies offering products. These include Novo Nordisk, Pfizer, Bayer, CSL Behring, and Shire. Additionally, there are several smaller companies that offer Factor VIII products, such as Octapharma, Kedrion, and Biotest. Show Less Read more